Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines: a Single-blinded, Randomized, Parallel Group Superiority Trial

NCT05668065 is registered in ClinicalTrials.gov with Institut Pasteur de Tunis as lead sponsor.

NCT NCT05668065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05668065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines: a Single-blinded, Randomized, Parallel Group Superiority Trial
Lead sponsor
Institut Pasteur de Tunis
Phase
Phase 3
Overall status
Completed
Start date
November 22, 2021
Completion date
June 25, 2022
Enrollment
199 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19